Proven and Commercial Core Technology To Create Bio Better & Bio Superior Products With Low Risk and Reduced Cost

1. Vitapharm Technology Development Proven and CommercialCore Technology To Create Bio Better & Bio Superior Products With Low Risk and Reduced Cost Thomas Sai-Ying Ko Chairman Vital HealthPoint Group

2. Agenda • Vitapharm IP • Bio Better and Bio Superior Sublingual Products • Interleukin 2 • Anti Cancer • Anti Inflammatory • Exenatide ( Byetta®) • Corporate Objectives • Alliance with CRO and Bio Pharmaceutical Co.

3. It’s your Choice • Vitapharm is currently seeking global alliance opportunities with BioPharma and CRO companies to maximize our sublingual tablet technology potential. • Vitapharm’s technology can readily recycle patent-expired products to provide enhanced therapeutic and market potential at lower cost and with minimal risk. • Our technology recreates patent-expired biologic actives into patentable, stable and more convenient Bio Better and Bio Superior sublingual tablets without any structural changes to the basic molecule. • More than 30 branded biologics worth $51 billion will lose patent exclusivity by 2015 ( Datamonitor, 2011 ). It is estimated to cost an average $100 million and up to 8 years to develop a Bio Similar.

4. Solution Vitapharm CSSR Obstacles in Biological Commercialization Protein Inherently Unstable Delivery Mostly By Invasive Injection User Friendly Sublingual Tablet Room Temperature Stable ( Bio Better ) Advantages • Expanded Treatment Indications • Improved Efficacy & Reduce Toxicity • New Patent Protection • ( Bio Superior )

5. Vitapharm CSSR Technology CSSR Biocapsule Biological proteins & peptides 3/12/2014 5 5

6. Off patent Bio active + Vitapharm CSSR = New Patent Bio Better & Bio Superior No change in original protein

7. Global market for biological drugs = US$ 80.56 Billion in 2008All Injectionswww.pipelinereview.com • Anti inflammatory vaccines = US$16.36 billion • Anti cancer vaccines = US$15.59 billion • IFN = US$7.95 billion. • EPO = US$10 billion. • G-CSF = US$5.18billion • HGH = US$2.68 billion • Ref – Special Edition 1/2009 top 20 Biologics - 2008 Sales of Antibodies & Proteins

8. Vitapharm China Projects IL2 Calcitonin EPO Vitapharm CSSR Technology Thymosine G-CSF Exenatide IFN HGH

9. Successful Sublingual Delivery of Interferon For HBV & HCV 3/12/2014 9

10. Vitapharm Bio Better Vitapharm CSSR Technology + EPO Beijing Four Rings Bio-Pharma Injections Beijing Four Rings Pharma + G-CSF IL2 + IL2 Vitapharm owns 45% equity of Beijing Four Rings Pharma Anti inflammation Cancer

11. Tom Ko intellectual property Patent applied for • IL2 anti cancer patent • IL2 anti inflammatory patent • IL2 anti fungal patent • Sublingual Slow Release Drug Delivery (CSSR) Patent

12. Agenda • Interleukin 2 • Anti Cancer • Anti inflammatory

13. The Cancer Market

14. Vitapharm Bio Better Vitapharm CSSR technology IL2 Injection is indicted for kidney Cancer and melanoma only New indication + Liver Renal IL2 Cancer New indication Stomach Melanoma

15. Summary of ( CSSR IL2 ) Animal Studies (liver, kidney, stomach, lung and skin tumor ) N= 660 Sublingual CSSR IL2 is more effective than IL2 injection in supression of tumor weight. Sublingual delivered CSSR IL2 has no obvious toxic side effects * p<0.05 ** p <0.01

16. The Antineoplastic Activities of a Novel Oral Formulation of Interleukin-2 (IL-2) Sen Zhang1, Thomas Sai-Ying Ko2, Ricky Runjiang Qu2, Xiaoguang Chen1, Mark Sullivan2, 3 1 Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing, China 2 Kambridge Life Sciences, Melbourne, Australia 3 Medicines Development Limited, Melbourne, Australia Poster Number: 125 Cytokine Sublingual Delivery System (CSDS) 20th EORTC/NCI/AACR Symposium, Geneva, Switzerland, 21-24, October, 2008 20 Kingsley Close Rowville Melbourne VIC Australia 3178 Tel: +61 3 97641744 Fax: +61 3 97641900 www.kambridgelifescience.com.au Tom Ko: tomkat888@gmail.com INTRODUCTION ►In Vivo Proteins or Peptides Dissolve and Release Interleukin2 has been proven to be effective in treatment of metastatic renal cell carcinoma, metastatic melanoma and other cancers. However, IL2 administered by injection has significant side effects. A novel oral (mucosal) formulation for cytokine delivery is being developed for human administration: the tumour growth inhibition efficacy of oral mucosally (muc) administrated recombinant human (rh) IL-2 in mice implanted with melanoma B16, murine renal cancer RENCA, gastric cancer or H22 liver cancer was evaluated. Fig. 3. Growth inhibition of murine kidney ( renal ) cancer after treatment by rhIL-2.IR of 10IU and 100IU muc rhIL-2 were 40.9**% and 47.7**%, respectively. IR of 100IU rhIL-2 sc was 32.3**%. MATERIALS AND METHODS RESULTS ►Animal Tumor Models Significant tumour growth inhibition of muc rhIL-2 occurred in a dose dependent manner (plateau between 10 and 100IU) and was similar to sc rhIL-2 for all 4 cancer models. There was no evidence of toxicity in any animal. CSDS Biocapsule Proteins or Peptides Fig. 4. Growth inhibition of murine stomach (gastric) cancer after treatment by rhIL-2. IR of 10IU and 100IU muc rhIL-2 were 27.7**% and 54.5**%,respectively. IR of 100IU rhIL-2 sc was 32.7**%. • ►Antineoplastic Treatment Groups • No treatment (Control) • Isotonic Saline (Placebo) • Subcutaneous injection rhIL-2 (100IU) • Oral mucosal rhIL-2 (1, 10, 100 or 500IU) All the above experiments were repeated once (results not shown). Conclusion • All the above results show muc rhIL-2 : • results in significant growth inhibition of liver, renal, melanoma and gastric cancer in the murine model • well tolerated and no side effects were observed ►Microencapsulation of Proteins/Peptides into Tablets by CSDS Fig. 1. Growth inhibition of murine liver cancer H22 after treatment by rhIL-2. IR was 45.2**% for 10IU muc rhIL-2, 59.5**% for 100IU muc rhIL-2 while 100IU sc rhIL-2 IR was 42.8**%. ADVANTAGE OF CSDS TECHNOLOGY • User friendly dosage from • Replace freeze dry technology • Improved efficacy • Lower production cost • Extended product life cycle • Expanded production cost • Prolonged patent protection Fig.2. Growth inhibition of murine skin cancer (Melanoma B16) after treatment by rhIL-2. IR was 10IU muc rhIL-2 was 44.4**% and 100IU muc rhIL-2 was 67.0**%. 100IU rhIL-2 sc IR was 34.0**%. Melbourne Australia • ►Experimental Endpoint • Body weights and extracted tumor weights recorded after sacrifice • Inhibition Rate calculated as the following: Weight of tumor control group – weight of tumor treatment group --------------------------------------------------------------------------------- Weight of tumor in control group Tumor reduction % =

17. CSSR IL2 Sublingual Tablets

18. Agenda • Interleukin 2 • Anti Cancer • Anti Inflammatory

19. Global Anti-Inflammatory Market $35.5 billion BBC Research : Therapeutics for Inflammatory Diseases: Current Challenges and Future Market Report Code: PHM048A Rheumatoid arthritis ( RA) $12.25 billion

20. Vitapharm Bio Superior IL2 Sublingual Tablets as Anti inflammatory sublingual IL2 treats the cause of the inflammatory disease by eliminating self reactive T cells. Vitapharm CSSR Technology Sinusitis IL2 Sublingual Tab Rheumatoid Arthritis Anti inflammatory Psoriasis

21. Sublingual CSSR IL2 Rheumatoid Arthritis Animal Study Swelling Day 23 N=50 Dose given twice daily ** ** **P<0.01 cf control ** ** Swelling Index Injection 16000IU/Kg Bwt Control No treatment Sublingual 4000IU/Kg Bwt Sublingual 12000IU/Kg Bwt Injection 4000IU/Kg Bwt IL2 injection or IL2 sublingual significantly reduce swelling and RA effects ** P>0.01

22. Sublingual CSSR IL2 Rheumatoid Arthritis Animal Study RA Index Day 23 N=50 Dose given twice daily ** **P<0.01 ** ** ** RA Index Control No treatment Sublingual 4000IU/Kg Bwt Sublingual 12000IU/Kg Bwt Injection 4000IU/Kg Bwt Injection 16000IU/Kg Bwt No toxicity observed in any treatment group. All IL2 treatment cf RA model group p<0.01 day 23 Sublingual IL2 provides earlier relief than injection. Higher dose provides best result on day 23

23. IL2 RA Experiment Markers IL1β(pg/ml) ✔ * ✔ * IL-6 (pg/ml) ✔ * TNF-α(pg/ml) ✔ CD4+CD25+:TReg * * P<0.05 cf RA model

24. IL2 as anti inflammatory Global Anti-Inflammatory Market For Rheumatoid Arthritis • Traditional chemical and steroid-based anti inflammatory drugs relieve pain only and do not treat the cause of the disease. • They all have major side effects ( e.g. stomach bleeding & ulcers ). • Receptor based biological treatment slow down the disease : tiw • Market for receptor based treatment was $9.45 billion in last 12 months. • Sublingual IL2 Tablets are a new method to treat the cause of the disease by eliminating the self reactive T cells. • Sublingual IL2 Tablet is ideal for Rheumatoid Arthritis ( RA) , Sinusitis, Prostate inflammation and other chronic inflammatory diseases.

25. Agenda Diabetic Market

26. Disadvantage of “Best” Drug Byetta® ( Exenatide) 3/12/2014 26

27. Exenatide Sublingual Tablet CSDS Biocapsule Exenatide • 39 amino-acid peptide • Formula: C184H282N50O60S • Molec Mass: 4186.6 3/12/2014 27 27

28. Fasting Plasma GlucoseHuman patient data 3/12/2014 28

29. Plasma Glucose 2h after mealHuman patent data

30. Contact us Vitapharm Technology Development Co. Ltd. Attention - Thomas S. Ko Chairman & Group Chief Scientist - Vital HealthPoint Group E mail : tomkat888@gmail.com tko@VHP.cn • Mailing address: • Suite 868, Poly Plaza Office Building. 14 Dongzhimen, NanDaiJie, Beijing, P.R. China. 100027. Tel: +8610- 65008667 Fax: +8610-65084084 • Office: Four Ring Pharma Building, 5 Jianan Rd., BDA, Beijing, P. R. China.